| 40.5 0 (0%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 47.37 | 1-year : | 55.33 |
| Resists | First : | 40.56 | Second : | 47.37 |
| Pivot price | 40.04  |
|||
| Supports | First : | 39.95 | Second : | 39.58 |
| MAs | MA(5) : | 40.5 |
MA(20) : | 39.98 |
| MA(100) : | 34.63 |
MA(250) : | 26.97 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 93.8 | D(3) : | 93.8  |
| RSI | RSI(14): 78.1 | |||
| 52-week | High : | 40.56 | Low : | 12.89 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CNTA ] has closed below upper band by 17.0%. Bollinger Bands are 68.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 47 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 40.54 - 40.73 | 40.73 - 40.9 |
| Low: | 40.02 - 40.25 | 40.25 - 40.45 |
| Close: | 40.16 - 40.51 | 40.51 - 40.82 |
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
Fri, 14 Aug 2026
Centessa Pharmaceuticals (CNTA): Index Ventures entities report 0% beneficial ownership - Stock Titan
Fri, 14 Aug 2026
Pentwater exits Centessa Pharmaceuticals (CNTA) with reported 0% ownership - Stock Titan
Wed, 24 Jun 2026
Centessa Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Thu, 04 Jun 2026
Assessing Centessa Pharmaceuticals (CNTA) Valuation After Strong Multi Period Share Price Gains - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 155 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 96.9 (%) |
| Shares Short | 1,610 (K) |
| Shares Short P.Month | 2,470 (K) |
| EPS | -1.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.5 % |
| Return on Equity (ttm) | -57.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -209 (M) |
| Levered Free Cash Flow | -129 (M) |
| PE Ratio | -22.76 |
| PEG Ratio | 0 |
| Price to Book value | 12.85 |
| Price to Sales | 0 |
| Price to Cash Flow | -30.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|